| Tdark | RIMS-binding protein 2 |
Plays a role in the synaptic transmission as bifunctional linker that interacts simultaneously with RIMS1, RIMS2, CACNA1D and CACNA1B.
Comments
| Disease | Target Count | P-value |
|---|---|---|
| lung carcinoma | 2843 | 6.1e-53 |
| glioblastoma | 5792 | 6.0e-07 |
| pituitary cancer | 1972 | 1.6e-06 |
| Astrocytoma, Pilocytic | 3081 | 1.8e-05 |
| atypical teratoid / rhabdoid tumor | 5112 | 2.0e-05 |
| adult high grade glioma | 3801 | 8.0e-04 |
| ependymoma | 4679 | 8.6e-04 |
| astrocytic glioma | 2597 | 2.3e-03 |
| oligodendroglioma | 2850 | 3.8e-03 |
| lung cancer | 4740 | 3.9e-03 |
| Pick disease | 1894 | 6.2e-03 |
| group 3 medulloblastoma | 4104 | 1.3e-02 |
| medulloblastoma, large-cell | 6241 | 1.3e-02 |
| colon cancer | 1478 | 2.0e-02 |
| Alzheimer's disease | 658 | 2.8e-02 |
| progressive supranuclear palsy | 676 | 3.5e-02 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| CD40 ligand deficiency | 2 | 4.989 | 2.5 |
| Spinocerebellar ataxia type 6 | 6 | 3.865 | 1.9 |
| Childhood absence epilepsy | 8 | 3.749 | 1.9 |
| Carpal tunnel syndrome | 20 | 3.233 | 1.6 |
| Disease | log2 FC | p |
|---|---|---|
| adult high grade glioma | -2.800 | 8.0e-04 |
| Alzheimer's disease | 1.200 | 2.8e-02 |
| astrocytic glioma | -2.900 | 2.3e-03 |
| Astrocytoma, Pilocytic | -2.600 | 1.8e-05 |
| atypical teratoid / rhabdoid tumor | -3.200 | 2.0e-05 |
| colon cancer | 2.600 | 2.0e-02 |
| ependymoma | -3.200 | 8.6e-04 |
| glioblastoma | -2.900 | 6.0e-07 |
| group 3 medulloblastoma | -3.100 | 1.3e-02 |
| lung cancer | 2.200 | 3.9e-03 |
| lung carcinoma | 3.200 | 6.1e-53 |
| medulloblastoma, large-cell | -2.400 | 1.3e-02 |
| oligodendroglioma | -2.600 | 3.8e-03 |
| Pick disease | -1.700 | 6.2e-03 |
| pituitary cancer | -2.000 | 1.6e-06 |
| progressive supranuclear palsy | 1.500 | 3.5e-02 |
MREAAERRQQLQLEHDQALAVLSAKQQEIDLLQKSKVRELEEKCRTQSEQFNLLSRDLEKFRQHAGKIDL 1 - 70 LGGSAVAPLDISTAPSKPFPQFMNGLATSLGKGQESAIGGSSAIGEYIRPLPQPGDRPEPLSAKPTFLSR 71 - 140 SGSARCRSESDMENERNSNTSKQRYSGKVHLCVARYSYNPFDGPNENPEAELPLTAGKYLYVYGDMDEDG 141 - 210 FYEGELLDGQRGLVPSNFVDFVQDNESRLASTLGNEQDQNFINHSGIGLEGEHILDLHSPTHIDAGITDN 211 - 280 SAGTLDVNIDDIGEDIVPYPRKITLIKQLAKSVIVGWEPPAVPPGWGTVSSYNVLVDKETRMNLTLGSRT 281 - 350 KALIEKLNMAACTYRISVQCVTSRGSSDELQCTLLVGKDVVVAPSHLRVDNITQISAQLSWLPTNSNYSH 351 - 420 VIFLNEEEFDIVKAARYKYQFFNLRPNMAYKVKVLAKPHQMPWQLPLEQREKKEAFVEFSTLPAGPPAPP 421 - 490 QDVTVQAGVTPATIRVSWRPPVLTPTGLSNGANVTGYGVYAKGQRVAEVIFPTADSTAVELVRLRSLEAK 491 - 560 GVTVRTLSAQGESVDSAVAAVPPELLVPPTPHPRPAPQSKPLASSGVPETKDEHLGPHARMDEAWEQSRA 561 - 630 PGPVHGHMLEPPVGPGRRSPSPSRILPQPQGTPVSTTVAKAMAREAAQRVAESSRLEKRSVFLERSSAGQ 631 - 700 YAASDEEDAYDSPDFKRRGASVDDFLKGSELGKQPHCCHGDEYHTESSRGSDLSDIMEEDEEELYSEMQL 701 - 770 EDGGRRRPSGTSHNALKILGNPASAGRVDHMGRRFPRGSAGPQRSRPVTVPSIDDYGRDRLSPDFYEESE 771 - 840 TDPGAEELPARIFVALFDYDPLTMSPNPDAAEEELPFKEGQIIKVYGDKDADGFYRGETCARLGLIPCNM 841 - 910 VSEIQADDEEMMDQLLRQGFLPLNTPVEKIERSRRSGRRHSVSTRRMVALYDYDPRESSPNVDVEAELTF 911 - 980 CTGDIITVFGEIDEDGFYYGELNGQKGLVPSNFLEEVPDDVEVYLSDAPSHYSQDTPMRSKAKRKKSVHF 981 - 1050 TP 1051 - 1052 //
